DeepMind spin-off steps up effort to use AI to create new drugs
Alphabet-owned Isomorphic Labs is ramping up its operations by poaching pharmaceutical talent and opening a new office, as the artificial intelligence drug discovery start-up moves closer to securing its first commercial deal.
The UK-registered group was spun out of its sister company DeepMind, Google’s AI unit, in November last year, to focus on using AI technology to create new drugs to treat and prevent diseases.
Isomorphic is currently in talks with major pharmaceutical companies and is expected to announce a deal in the next few months, according to two people familiar with the plans.
This story originally appeared on: Financial Times - Author:Ian Johnston
